- Home
- APLT vs FGEN Comparison
APLT vs FGEN Comparison
Compare APLT & FGEN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- APLT
- FGEN
- Stock Information
- Founded
- APLT 2016
- FGEN 1993
- Country
- APLT United States
- FGEN United States
- Employees
- APLT N/A
- FGEN N/A
- Industry
- APLT Biotechnology: Pharmaceutical Preparations
- FGEN Biotechnology: Pharmaceutical Preparations
- Sector
- APLT Health Care
- FGEN Health Care
- Exchange
- APLT Nasdaq
- FGEN Nasdaq
- Market Cap
- APLT 37.5M
- FGEN 33.5M
- IPO Year
- APLT 2019
- FGEN 2014
- Fundamental
- Price
- APLT $0.33
- FGEN $0.29
- Analyst Decision
- APLT Buy
- FGEN Strong Buy
- Analyst Count
- APLT 7
- FGEN 1
- Target Price
- APLT $6.10
- FGEN $10.00
- AVG Volume (30 Days)
- APLT 2.3M
- FGEN 1.2M
- Earning Date
- APLT 04-14-2025
- FGEN 05-05-2025
- Dividend Yield
- APLT N/A
- FGEN N/A
- EPS Growth
- APLT N/A
- FGEN N/A
- EPS
- APLT N/A
- FGEN N/A
- Revenue
- APLT $455,000.00
- FGEN $29,621,000.00
- Revenue This Year
- APLT $3,031.87
- FGEN $232.81
- Revenue Next Year
- APLT $312.01
- FGEN $9.16
- P/E Ratio
- APLT N/A
- FGEN N/A
- Revenue Growth
- APLT N/A
- FGEN N/A
- 52 Week Low
- APLT $0.30
- FGEN $0.18
- 52 Week High
- APLT $10.62
- FGEN $1.74
- Technical
- Relative Strength Index (RSI)
- APLT 36.05
- FGEN 41.77
- Support Level
- APLT $0.30
- FGEN $0.23
- Resistance Level
- APLT $0.38
- FGEN $0.31
- Average True Range (ATR)
- APLT 0.05
- FGEN 0.03
- MACD
- APLT -0.00
- FGEN 0.01
- Stochastic Oscillator
- APLT 17.19
- FGEN 55.45
About APLT Applied Therapeutics Inc.
Applied Therapeutics Inc is a clinical-stage biopharmaceutical company, developing a pipeline of novel product candidates against validated molecular targets in indications of high unmet medical need. The company's drug compounds pipeline includes, AT-007 which is a novel central nervous system, penetrant ARI that it is developing for the treatment of rare metabolic diseases, including Galactosemia and Sorbitol Dehydrogenase (SORD) Deficiency, AT-001 for the treatment of diabetic cardiomyopathy, and AT-003 for the treatment of diabetic retinopathy.
About FGEN FibroGen Inc
FibroGen Inc is a biotechnology company focused on discovering, developing, and commercializing novel therapeutics to treat serious cancer biology and anemia. The company operates in one reportable segment: the development and commercialization of novel therapeutics to treat serious unmet medical needs. The company generates the vast majority of its revenue in Europe, followed by Japan. Virtually all of FibroGen's revenue to date has been generated from its collaboration agreements. FibroGen seeks partners with research, development, and marketing capabilities and other resources that strengthen the company's ability to advance product candidates. Geographically, it operates in United States, Japan, Europe and Others.